Meanwhile, the HHS website scrubbed search results for the word "abortion," and ReproductiveRights.gov -- a site the Biden administration launched after the Supreme Court overturned Roe v. Wade -- is now a broken link. ( NPR)

A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer's CEO during negotiations for Covid shots.

Atara Biotherapeutics said on Tuesday the U.S. health regulator has placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket trading.

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

Over 35 years after the first study linking Red 3 to thyroid cancer in rats was published, the US is beginning to wean it out of foods and drugs.

Over the years, an increasing number of studies have linked formaldehyde to cancers that are especially prevalent among Black women.

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

FDA officials have telegraphed the decision for months. While the agency has long said that it did not think evidence of Red 3 causing cancer applied to humans, officials said their hand was forced by a law requiring the agency to pull additives that are cancerous in animals.

After decades of debate, the Food and Drug Administration (FDA) has announced a ban on Red Dye No. 3, a synthetic food coloring that’s been linked to cancer in male lab rats. The decision comes after a petition filed in 2022 by advocacy groups,

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market opportunity analysts estimate to be worth about $500 million annually.

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication applies to use of the agent by adults with hormone receptor-positive, HER2-negative breast cancer who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.